Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • Aironite: Phase IIa data

    Mast Therapeutics Inc. (NYSE-M:MSTX), San Diego, Calif. Product: Aironite (AIR001) Business: Cardiovascular Molecular target: NA Description: Inhaled nebulized sodium nitrite Indication: Treat heart failure with …

    Published on 2/8/2016
  • Anti-LPA antibody: Phase Ia data

    Lpath Inc. (NASDAQ:LPTN), San Diego, Calif. Product: Anti-LPA antibody, Lpathomab Business: Neurology Molecular target: Lysophosphatidic acid (LPA) Description: Human mAb against lysophosphatidic acid (LPA) Indication: …

    Published on 2/8/2016
  • CAP7: Preliminary Phase II data

    CellAct Pharma GmbH, Dortmund, Germany Product: CAP7.1 Business: Cancer Molecular target: Topoisomerase II (TOP2) Description: Small molecule etoposide prodrug and topoisomerase II (TOP2) inhibitor Indication: Treat …

    Published on 2/8/2016
  • CHS-1701: Phase I data

    Coherus BioSciences Inc. (NASDAQ:CHRS), Redwood City, Calif. Product: CHS-1701 Business: Hematology Molecular target: Granulocyte colony-stimulating factor (G-CSF) (CSF3) Description: Biosimilar of pegfilgrastim, a …

    Published on 2/8/2016
  • Cometriq cabozantinib: Additional Phase III data

    Exelixis Inc. (NASDAQ:EXEL), South San Francisco, Calif. Product: Cometriq cabozantinib (XL184) Business: Cancer Molecular target: Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1); c-Met …

    Published on 2/8/2016
  • CPI-613: Phase I data

    Cornerstone Pharmaceuticals Inc., Cranbury, N.J. Product: CPI-613 Business: Cancer Molecular target: Pyruvate dehydrogenase (PDH) Description: Analog of alpha-lipoic acid that targets the mitochondrial enzymes pyruvate …

    Published on 2/8/2016
  • ECCS-50: Phase I data

    Cytori Therapeutics Inc. (NASDAQ:CYTX), San Diego, Calif. Product: ECCS-50, Adipose-derived regenerative cells (ADRCs) (Cytori Cell Therapy) Business: Genitourinary Molecular target: Not available Description: …

    Published on 2/8/2016
  • EscharEx: Phase II data

    MediWound Ltd. (NASDAQ:MDWD), Yavne, Israel Product: EscharEx Business: Dermatology Molecular target: NA Description: Enzymatic debriding agent Indication: Treat chronic and other hard-to-heal wounds Endpoint: Incidence…

    Published on 2/8/2016
  • HC-LD Cream: Phase IIa data

    Citius Pharmaceuticals Inc. (OTCQB:CTXR), Maynard, Mass. Product: HC-LD Cream Business: Gastrointestinal Molecular target: NA Description: Topical cream comprised of hydrocortisone and lidocaine Indication: Treat …

    Published on 2/8/2016
  • MIN-202: Phase I data

    Minerva Neurosciences Inc. (NASDAQ:NERV), Cambridge, Mass. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: MIN-202, JNJ-42847922 Business: Neurology Molecular target: Orexin 2 receptor (OX2R) (HCRTR2) …

    Published on 2/8/2016
  • Ovax: Phase I/II data

    Avax Technologies Inc. (Pink:AVXT), Philadelphia, Pa. Product: Ovax Business: Cancer Molecular target: Not available Description: Hapten-modified autologous ovarian tumor cell vaccine Indication: Treat advanced ovarian …

    Published on 2/8/2016
  • Padeliporfin di-potassium: Phase III data

    Steba Biotech Ltd., Luxembourg, Luxembourg Product: Padeliporfin di-potassium (Tookad) Business: Cancer Molecular target: NA Description: Soluble-mediated vascular targeted photodynamic (VTP) therapy that uses a …

    Published on 2/8/2016
  • PreTRM test: Clinical trial data

    Sera Prognostics Inc., Salt Lake City, Utah Product: PreTRM test Business: Diagnostic Molecular target: NA Description: Blood test for detecting the risk of spontaneous preterm birth in asymptomatic, singleton …

    Published on 2/8/2016
  • Staphylococcus lysin: Phase I data

    ContraFect Corp. (NASDAQ:CFRX), Yonkers, N.Y. Product: Staphylococcus lysin (CF-301) Business: Infectious Molecular target: NA Description: Staphylococcal-specific lysin protein Indication: Treat Staphylococcus …

    Published on 2/8/2016
  • Topsalysin: Preliminary Phase IIa data

    Sophiris Bio Inc. (NASDAQ:SPHS), La Jolla, Calif. Kissei Pharmaceutical Co. Ltd. (Tokyo:4547), Nagano, Japan Product: Topsalysin (PORxin) (PRX302) (formerly PSA-PAH1) Business: Cancer Molecular target: …

    Published on 2/8/2016
  • Tresiba insulin degludec: Phase IIIb data

    Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark Product: Tresiba insulin degludec (NN1250) Business: Endocrine/Metabolic Molecular target: Insulin receptor (INSR) Description: Long-acting insulin analog …

    Published on 2/8/2016
  • Trimesta: Additional Phase II data

    Synthetic Biologics Inc. (NYSE-M:SYN), Rockville, Md. Product: Trimesta Business: Autoimmune Molecular target: NA Description: Oral estriol, a pregnancy hormone Indication: Treat relapsing-remitting multiple sclerosis (…

    Published on 2/8/2016
  • TT-401: Phase II data

    Transition Therapeutics Inc. (TSX:TTH; NASDAQ:TTHI), Toronto, Ontario Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: TT-401, LY2944876, TT401 Business: Endocrine/Metabolic Molecular target: Glucagon-like …

    Published on 2/8/2016
  • Tumor Treating Fields: Phase II data

    Novocure Ltd. (NASDAQ:NVCR), Isle of Jersey Product: Tumor Treating Fields (TTFields), NovoTTF-100L Business: Cancer Molecular target: NA Description: Low intensity, alternating electric fields in the intermediate …

    Published on 2/8/2016
  • TW001: Phase I data

    Treeway B.V., Rotterdam, the Netherlands Product: TW001 Business: Neurology Molecular target: Free radical Description: Oral formulation of edaravone, a free radical scavenger cerebral neuroprotectant Indication: Treat …

    Published on 2/8/2016
  • Valbenazine: Phase Ib data

    Neurocrine Biosciences Inc. (NASDAQ:NBIX), San Diego, Calif. Mitsubishi Tanabe Pharma Corp. (Tokyo:4508), Osaka, Japan Product: Valbenazine (NBI-98854) Business: Neurology Molecular target: Vesicular monoamine …

    Published on 2/8/2016
  • 2-Gene Colorectal Cancer Recurrence Test: Clinical trial data

    Clinical Genomics Pty. Ltd., North Ryde, Australia Product: 2-Gene Colorectal Cancer Recurrence Test Business: Diagnostic Molecular target: NA Description: Blood test that detects tumor-specific methylated cytosolic …

    Published on 2/1/2016
  • Birinapant: Phase II discontinued

    TetraLogic Pharmaceuticals Corp. (NASDAQ:TLOG), Malvern, Pa. Product: Birinapant (formerly TL32711) Business: Cancer Molecular target: Inhibitor of apoptosis (IAP) Description: Small molecule peptidomimetic of diablo …

    Published on 2/1/2016
  • CaCP29: Phase IIa data

    InflaRx GmbH, Jena, Germany Product: CaCP29, IFX-1 Business: Infectious Molecular target: Complement 5a (C5a) Description: mAb against complement 5a (C5a) Indication: Treat septic organ dysfunction Endpoint: Safety, …

    Published on 2/1/2016
  • CAT-1004: Phase I/II data

    Catabasis Pharmaceuticals Inc. (NASDAQ:CATB), Cambridge, Mass. Product: CAT-1004 Business: Musculoskeletal Molecular target: Nuclear factor of kappa light polypeptide gene enhancer in B cells 1 (NF-kB) (NFKB1) (p105) (…

    Published on 2/1/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993